We are live on
!
Find out more
TG
TRV GP Portfolio holdings
AUM
$18.9M
1-Year Est. Return
541.67%
This Fund
S&P 500
This Quarter
Est. Return
-11.47%
1 Year Est. Return
+541.67%
3 Year Est. Return
+3,178.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$141M
AUM Growth
-$80.2M
(-36%)
Cap. Flow
-$65.6M
Cap. Flow
% of AUM
-46.52%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
1
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
CytomX Therapeutics
CTMX
|
+$65.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Rhythm Pharmaceuticals
RYTM
$7.28B
| $79.2M | 56.15% |
3,981,437
| – | – |
|
|
2
CytomX Therapeutics
CTMX
$798M
| $29M | 20.57% |
1,020,348
-2,300,000
| -69% | -$65.6M |
|
3
KALA BIO
KALA
$15.7M
| $26.2M | 18.56% |
662
| – | – |
|
|
CARM
4
DELISTED
Carisma Therapeutics
CARM
| $5.08M | 3.6% |
242,080
| – | – |
|
5
Larimar Therapeutics
LRMR
$381M
| $1.57M | 1.11% |
17,531
| – | – |
|
Similar funds
KA
FRGX
DHRFI
SA
YECIP
FFIM
ES
HCMT
TRV GP's Q1 2018 Portfolio in Review
As of Q1 2018, TRV GP held 5 positions worth $141M, down 36% from $221M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
TRV GP withdrew a net $65.6M in Q1 2018, reducing 1 holding. Its largest reduction was CytomX Therapeutics, cutting an estimated $65.6M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- TRV GP's biggest Q1 2018 reduction was CytomX Therapeutics, cutting an estimated $65.6M.
- TRV GP's ten largest holdings make up 100% of its $141M portfolio in Q1 2018.
- TRV GP opened 0 new positions and closed 0 in Q1 2018.
- TRV GP's portfolio value fell 36% quarter-over-quarter to $141M.
Based on TRV GP's 13F filing for Q1 2018, filed 19 Apr 2018.